IRVINE, CA (PRWEB) OCTOBER 06, 2015
Bioniz, a biopharmaceutical company leading the discovery and development of first-in-class multiple-cytokine inhibitory therapeutics to address immunoinflammatory diseases and cancer immune-therapy, announced today its first two scientific publications in the prestigious peer-reviewed journals JBC and PNAS.
“These publications validate how Bioniz’s novel technology effectively selects and targets biologically redundant cytokines, an unprecedented functionality, which we believe will lead to the creation of a new and major class of drugs that comprehensively address the multiple drivers characteristic of immune system diseases,” said Nazli Azimi, CEO of Bioniz and co-inventor of the technology. “The issue of cytokine redundancy has been an obstacle to the development of effective anti-cytokine therapies. The current therapeutic approaches have been limited either to single monoclonal antibody (MAB) therapies against individual cytokines or to the use of JAK inhibitors that too broadly and non-exclusively block the downstream signaling components that follow cytokine activation. Humira, the monoclonal antibody set to eclipse Lipitor as the largest drug of all time, exemplifies the vast market potential of cytokine modulation. Even though Humira targets only one cytokine and is not highly specific to many of the disease states that have adopted it, it has still shown tremendous success for patients and created incredible market value. We hope to contribute such value many fold.”
JBC: Bioniz scientists and collaborators demonstrated in the JBC (J Biol Chem. 2015 Sep 11;290(37):22338-51) a proprietary design algorithm by which specific peptide molecules may be created that each selectively inhibit multiple cytokines with overlapping functions, and that act without compromising the broader cytokine family. More specifically, they demonstrated that BNZ132-1, a peptide that selectively inhibits IL-2, IL-9, and IL-15, has in vitro and in vivo efficacy comparable with combinatorial MABs against each cytokine.
PNAS: The second publication in PNAS (PNAS September 1, 2015 vol. 112no. 35 11030-11035 ) details extensive studies conducted at a leading laboratory for neuro-inflammatory diseases at the NIH. The manuscript details the positive results of BNZ132-1, and its conjugated form, BNZ132-1-40, on modulation of the hyper-immune activity in HAM/TSP patients. HAM/TSP is an underserved and orphan status neuro- inflammatory disease with an MS-like clinical progression. This research sets the stage for Bioniz’s first Investigational New Drug Application, expected to be filed in 2016.
“We are very pleased with our progress and the fact that our collaborators have validated and acknowledged the potential of our technology” said Dr. Azimi. “These publications coincide with Company’s series A financing to initiate our clinical programs in orphan diseases. We are confident that with the robustness in our platform and rapid advancement of our pipeline, we will continue to generate significant value for our investors.”
Bioniz is a biopharmaceutical company leading the discovery and development of first-in-class multiple-cytokine inhibitory therapeutics to address immuno-inflammatory diseases and cancer, with an initial focus on orphan diseases. Bioniz leverages a world class expertise in cytokine biology, originating in research conducted at the National Institutes of Health, to create a therapeutic platform and a new generation of multiple-cytokine inhibitors with selective specificity. Selective targeting of multiple cytokines that have redundant functions improves on the traditional approach of single anti-cytokine therapy and therefore increases the therapeutic potential of Bioniz compounds. Bioniz’s technology is protected by US and international patents, which are solely owned by Bioniz. For more information, please visit http://www.bioniz.com.